This eye disease often leads to blindness — which might be prevented by early intervention
The team headed by Dr. Jacqueline Reinhard and Prof. Dr. Andreas Faissner from the Department of Cell Morphology and Molecular Neurobiology in Bochum, together with colleagues from the University Eye Clinic in Bochum, RWTH Aachen University, the University of Toronto and the University of Denver, has published a report on their findings. The article was released on 12 October 2018 in the online edition of the journal Molecular Neurobiology.
Specific and early intervention
The researchers bred mice in which the gene PTP-Meg2 (protein tyrosine phosphatase megakaryocyte 2) was mutated . As a result, the animals suffered from chronic intraocular pressure elevation. The team successfully demonstrated that, in their model, the intraocular pressure elevation was associated with a loss of optic nerve fibres and retinal cells. Using functional analyses, they observed that retinal cells were unable to function properly, either. Moreover, they made the following discovery: glial cells and certain components of the immune system showed a reaction in the animals’ optic nerve and retina. As both aspects may be relevant for neurodegeneration, specific and early intervention into these cellular mechanisms may inhibit glaucoma.
Testing new therapy options
Making use of a genetic screening, the researchers subsequently identified new potential biomarkers. In future, these biomarkers may facilitate early detection of glaucoma; as a result, it will be possible to start therapy at an early stage, before the optic nerve and retina are damaged. The glaucoma-mouse model may, moreover, be used to test new therapy options. Experiments to date have shown that intraocular pressure was reduced and nerve cells were retained in the mice if they were given a drug that had been administered to treat human patients.
The Latest on: Glaucoma
via Google News
The Latest on: Glaucoma
- SPARC Reports Positive Results from Phase 3 Clinical Trial of PDP-716 for Treatment of Open Angle Glaucomaon May 14, 2021 at 3:39 pm
Sun Pharma Advanced Research Company Ltd. (SPARC) on Friday, May 14, 2021, reported positive top-line results from its Phase 3 trials (CLR_16_33) for its investigational drug, PDP-716 ...
- Determinants of vessel defects in superficial and deep vascular layers in normal-tension glaucoma using optical coherence tomography angiographyon May 10, 2021 at 5:00 pm
We investigated the characteristics of localized vessel density defects (VD) either in the deep or superficial vascular layer of normal-tension glaucoma patients using optical coherence tomography ...
- Infographic: Advanced Glaucoma Intervention Study (AGIS)on May 10, 2021 at 8:20 am
The Advanced Glaucoma Intervention Study (AGIS): 4. Comparison of treatment outcomes within race. Seven-year results. Ophthalmology. 1998;105(7):1146–64.
- Doctors Are Shocked that this Herbal Remedy Restores Eyesight, Improves Vision and Reverses Glaucoma, Cataracts in few weeks!on May 8, 2021 at 5:00 am
But my eye doctor told me I could only live with it, so my optician kept on recommending eye glasses lens (or spectacles) so I could manage it ...
- BELKIN Laser Completes Enrollment of its GLAUrious Pivotal Trial for Glaucoma Laser Treatment in Secondson May 6, 2021 at 9:28 am
PRNewswire/ - BELKIN Laser, the Israel-based start-up bringing a fast, automated and non-invasive glaucoma laser treatment to market announced today that it has completed enrollment in its GLAUrious ...
- Glaucoma and Cataract Surgery Devices Market Trend Expected To Boost - Johnson & Johnson, Alcon Inc and New World Medical Incon May 6, 2021 at 12:27 am
MarketResearch.Biz one of the world’s prominent marketing research firm has launched a brand new report on Global Glaucoma and Cataract Surgery Devices Market. The report is complete of critical ...
- Low macular pigment levels novel risk factor for glaucoma among older womenon May 5, 2021 at 7:00 am
Rockville, Md. - New research out of the University of Wisconsin-Madison, identified an inverse reaction between macular pigment levels and open-angle glaucoma in a 15-year follow-up cohort of ...
- Global Glaucoma Epidemiology and Patient Flow Report 2021: Market Sizing, Potential, and Drug Forecast Models 2020-2035 - ResearchAndMarkets.comon May 5, 2021 at 2:16 am
The “Global Glaucoma Epidemiology and Patient Flow - 2021” report has been added to ResearchAndMarkets.com’s offering. The research report, Global Glaucoma Epidemiology and Patient Flow Analysis - ...
- Scientists identify genetic mutation associated with exfoliation syndrome known to cause glaucomaon May 4, 2021 at 6:31 pm
A team of researchers from the Agency for Science, Technology and Research's Genome Institute of Singapore and Bioprocessing Technology Institute, as well as Singapore Eye Research Institute, have ...
via Bing News